Journal article

Intra-Anal Imiquimod Cream against Human Papillomavirus Infection in Men Who Have Sex with Men Living with HIV: A Single-Arm, Open-Label Pilot Study

Duygu Durukan, Tiffany R Phillips, Gerald L Murray, Jason J Ong, Andrew E Grulich, I Mary Poynten, Fengyi Jin, Catriona S Bradshaw, Ivette Aguirre, Julie Silvers, Helen Kent, Steph Atchison, Prisha Balgovind, Alyssa Cornall, Marcus Y Chen, Christopher K Fairley, Eric PF Chow



Men who have sex with men (MSM) living with HIV have a high prevalence and incidence of anal high-risk human papillomavirus (hrHPV) and anal cancer. We conducted an open-label, single-arm pilot study to examine the tolerability of imiquimod cream among MSM aged ≥18 years, living with HIV, who tested positive for anal hrHPV at Melbourne Sexual Health Centre between April 2018 and June 2020. We instructed men to apply 6.25 mg imiquimod intra-anally and peri-anally 3 doses per week for 16 weeks (period 1) and then one dose per week for a further 48 weeks (period 2). Twenty-seven MSM enrolled in period 1 and 24 (86%) applied at least 50% of doses. All men reported adverse events (AEs), including..

View full abstract


Awarded by Australian National Health and Medical Research Council (NHMRC) Program Grant

Awarded by NHMRC Emerging Leadership Investigator Grant

Awarded by NHMRC Leadership Investigator Grant

Funding Acknowledgements

This trial was funded by an Australian National Health and Medical Research Council (NHMRC) Program Grant (GNT568971). E.P.F.C. and J.J.O. are supported by an NHMRC Emerging Leadership Investigator Grant (GNT1172873 and 1193955, respectively). C.K.F. and C.S.B. are each supported by an NHMRC Leadership Investigator Grant (GNT1172900 and GNT1173361, respectively).